Merck buys VC-backed Chord Therapeutics

Merck has acquired Chord Therapeutics, a developer of drugs for rare neuroinflammatory diseases.

20 December 2021•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs